These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25209360)

  • 41. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
    Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
    Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
    Baek ML; Lee J; Pendleton KE; Berner MJ; Goff EB; Tan L; Martinez SA; Mahmud I; Wang T; Meyer MD; Lim B; Barrish JP; Porter W; Lorenzi PL; Echeverria GV
    Oncogene; 2023 Mar; 42(14):1117-1131. PubMed ID: 36813854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.
    Wu M; Neilson A; Swift AL; Moran R; Tamagnine J; Parslow D; Armistead S; Lemire K; Orrell J; Teich J; Chomicz S; Ferrick DA
    Am J Physiol Cell Physiol; 2007 Jan; 292(1):C125-36. PubMed ID: 16971499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway.
    Wang Q; Ma L; Chen L; Chen H; Luo M; Yang W; Liao F; Gong Q; Wang Y; Yang Z; Wu J; Zhang C; Zheng J; Han S; Leng Y; Luo P; Shi C
    Biochem Biophys Res Commun; 2021 Mar; 544():65-72. PubMed ID: 33524870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathology of triple negative breast cancer.
    Borri F; Granaglia A
    Semin Cancer Biol; 2021 Jul; 72():136-145. PubMed ID: 32544511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic phenotypes in triple-negative breast cancer.
    Kim S; Kim DH; Jung WH; Koo JS
    Tumour Biol; 2013 Jun; 34(3):1699-712. PubMed ID: 23443971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.
    Sang R; Yu X; Xia H; Qian X; Yong J; Xu Y; Sun Y; Yao Y; Zhou J; Zhuo S
    Mol Carcinog; 2024 Apr; 63(4):785-796. PubMed ID: 38289126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
    Tailor D; Going CC; Resendez A; Kumar V; Nambiar DK; Li Y; Dheeraj A; LaGory EL; Ghoochani A; Birk AM; Stoyanova T; Ye J; Giaccia AJ; Le QT; Singh RP; Sledge GW; Pitteri SJ; Malhotra SV
    Br J Cancer; 2021 Feb; 124(3):604-615. PubMed ID: 33139797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer.
    Ito K; Ogata H; Honma N; Shibuya K; Mikami T
    Pathobiology; 2019; 86(5-6):315-321. PubMed ID: 31707383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.
    Kaur P; Nagaraja GM; Zheng H; Gizachew D; Galukande M; Krishnan S; Asea A
    BMC Cancer; 2012 Mar; 12():120. PubMed ID: 22452810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
    Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
    Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-throughput, Label-Free Quantitative Proteomic Studies of the Anticancer Effects of Electrical Pulses with Turmeric Silver Nanoparticles: an in vitro Model Study.
    Mittal L; Camarillo IG; Varadarajan GS; Srinivasan H; Aryal UK; Sundararajan R
    Sci Rep; 2020 Apr; 10(1):7258. PubMed ID: 32350346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.